$1.6 million grant for cancer drug programme - AustraliaAntibody therapeutics company EvoGenix Limited (ASX:EGX) today announced that it had been offered a grant of $1.66 million to fast track development of its anti-cancer antibody, DMF10. 7/5/06 The PDF files on this page require the free Adobe Acrobat Reader. |
International Relations
Information
Opportunities
What's happening?
Learn More
|
 |
|
|
|||||||||||||||||||
|
International RelationsNewsPrivacy Policy | Site Map | Contact the Webmaster
This page last updated on March 20, 2013. |
|
|||||||||||||||||||
|
|
|
|||||||||||||||||||
This is an